Use of letermovir in umbilical cord blood transplantation based on risk scores

Blood Adv. 2023 Aug 22;7(16):4315-4318. doi: 10.1182/bloodadvances.2023010573.

Monica M Rivera Franco¹, Hanadi Rafii¹, Fernanda Volt¹, Chantal Kenzey¹, Barbara Cappelli^{1

2}, Graziana Maria Scigliuolo^{1

2}, Vanderson Rocha^{1

3}, Nicole Raus⁴, Jean-Hugues Dalle⁵, Patrice Chevallier⁶, Marie Robin⁷, Marie Thérèse Rubio⁸, Annalisa Ruggeri^{1

9}, Eliane Gluckman^{1

2}

¹ Eurocord, Hôpital Saint Louis APHP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris Cité, Paris, France.
² Monacord, Centre Scientifique de Monaco, Monaco, Monaco.
³ Service of Hematology, Transfusion and Cell Therapy, and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Hospital das Clínicas, Faculty of Medicine, São Paulo University, São Paulo, Brazil.
⁴ Service d'Hématologie Clinique, Centre Hospitalier Lyon Sud - Hospices Civils de Lyon, Lyon, France.
⁵ Department of Hematology and Immunology, Hôpital Universitaire Robert-Debré, Paris, France.
⁶ Hematology Department, Hôtel-Dieu - CHU de Nantes, Nantes, France.
⁷ Service d'Hématologie-Greffe, Hôpital Saint Louis APHP, Université de Paris Cité, Paris, France.
⁸ Department of Hematology, Hôpital Brabois, Nancy, France.
⁹ Hematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.

No abstract available

Publication types